Based on the findings from this study, BP-LCN formulation presents as a promising therapeutic candidate against NSCLC by regulating apoptosis and cell proliferation, associated with the functions of survivin, hif-1α and p27KIP1. The gene discussed is CDKN1B; the disease is non-small cell lung carcinoma.